

SUPPLEMENTARY DATA

Supplementary Table 1. Nineteen independent genetic variants associated with fasting insulin as reported in the most recent Meta-Analysis of Glucose and Insulin Consortium (MAGIC) genome wide association study (1).

variant	Chr	Position	Gene	Alleles (effect/other)	EAF
rs10195252	2	165221337	<i>GRB14</i>	T/C	0.6
rs1167800	7	75014132	<i>HIP1</i>	A/G	0.54
rs1421085	16	52358455	<i>FTO</i>	C/T	0.42
rs1530559	2	135472099	<i>YSK4</i>	A/G	0.52
rs17036328	3	12365484	<i>PPARG</i>	T/C	0.86
rs2126259	8	9222556	<i>PPP1R3B</i>	T/C	0.11
rs2745353	6	127494628	<i>RSPO3</i>	T/C	0.51
rs2943645	2	226807424	<i>IRS1</i>	T/C	0.63
rs3822072	4	89960292	<i>FAM13A</i>	A/G	0.48
rs459193	5	55842508	<i>ANKRD55-MAP3K1</i>	G/A	0.73
rs4846565	1	217788727	<i>LYPLAL1</i>	G/A	0.67
rs4865796	5	53308421	<i>ARL15</i>	A/G	0.67
rs6822892	4	157954125	<i>PDGFC</i>	A/G	0.68
rs6912327	6	34872900	<i>UHRF1BP1</i>	T/C	0.8
rs731839	19	38590905	<i>PEPD</i>	G/A	0.34
rs7903146	10	114748339	<i>TCF7L2</i>	C/T	0.72
rs974801	4	106290513	<i>TET2</i>	G/A	0.38
rs780094	2	27594741	<i>GCKR</i>	C/T	0.61
rs35767	12	101399699	<i>IGF1</i>	G/A	0.82

SUPPLEMENTARY DATA

Supplementary Table 2. 32 variants associated with BMI from the Genetic Investigation of ANthropometric Traits (GIANT) consortium (2).

variant	Chr	Position	Gene	Alleles (effect/other)	EAF
rs2867125	2	612,827	<i>TMEM18</i>	C/T	0.83
rs571312	18	55,990,749	<i>MC4R</i>	A/C	0.24
rs10938397	4	44,877,284	<i>GNPDA2</i>	G/A	0.43
rs10767664	11	27,682,562	<i>BDNF</i>	A/T	0.78
rs2815752	1	72,585,028	<i>NEGR1</i>	A/G	0.61
rs7359397	16	28,793,160	<i>SH2B1</i>	T/C	0.4
rs9816226	3	187,317,193	<i>ETV5</i>	T/A	0.82
rs3817334	11	47,607,569	<i>MTCH2</i>	T/C	0.41
rs29941	19	39,001,372	<i>KCTD15</i>	G/A	0.67
rs543874	1	176,156,103	<i>SEC16B</i>	G/A	0.19
rs987237	6	50,911,009	<i>TFAP2B</i>	G/A	0.18
rs7138803	12	48,533,735	<i>FAIM2</i>	A/G	0.38
rs10150332	14	79,006,717	<i>NRXN3</i>	C/T	0.21
rs713586	2	25,011,512	<i>RBJ</i>	C/T	0.47
rs12444979	16	19,841,101	<i>GPRC5B</i>	C/T	0.87
rs2241423	15	65,873,892	<i>MAP2K5</i>	G/A	0.78
rs2287019	19	50,894,012	<i>QPCTL</i>	C/T	0.8
rs1514175	1	74,764,232	<i>TNNI3K</i>	A/G	0.43
rs13107325	4	103,407,732	<i>SLC39A8</i>	T/C	0.07
rs2112347	5	75,050,998	<i>FLJ35779</i>	T/G	0.63
rs10968576	9	28,404,339	<i>LRRN6C</i>	G/A	0.31
rs3810291	19	52,260,843	<i>TMEM160</i>	A/G	0.67
rs887912	2	59,156,381	<i>FANCL</i>	T/C	0.29
rs13078807	3	85,966,840	<i>CADM2</i>	G/A	0.2
rs11847697	14	29,584,863	<i>PRKD1</i>	T/C	0.04
rs2890652	2	142,676,401	<i>LRP1B</i>	C/T	0.18
rs1555543	1	96,717,385	<i>PTBP2</i>	C/A	0.59
rs4771122	13	26,918,180	<i>MTIF3</i>	G/A	0.24
rs4836133	5	124,360,002	<i>ZNF608</i>	A/C	0.48
rs4929949	11	8,561,169	<i>RPL27A</i>	C/T	0.52
rs206936	6	34,410,847	<i>NUDT3</i>	G/A	0.21

SUPPLEMENTARY DATA

Supplementary Table 3. Details of metabolic disease outcomes.

Metabolic disease outcomes	N studies	N individuals per study	Ethnicity	Covariates	Trait definition/measurement	Range of age mean across studies	Range of BMI mean across studies	REF (PMCID)
Type 2 diabetes	12	269-1,924 cases	European descent	Study-specific covariates, including indicators of population structure	Doctor diagnosed diabetes without insulin treatment in the first year and for most studies includes exclusion of individuals with GAD antibodies and monogenic forms of diabetes based on clinical criteria	44-68	26-31	PMC3442244
Coronary artery disease	14	278- 6640 cases	European descent	sex and age	1 artery with >50% stenosis in angiography, MI based on ECG and enzymes, PTCA or CABG	42-75	27-32	PMC3679547
Systolic and diastolic blood pressure	29	562-8096	European descent	age, age2, sex, BMI and other appropriate covariates (e.g. pc)	Blood pressure was measured using either an automated machine or a mercury column sphygmomanometer on upper arm with the subject in the sitting position after sitting quietly for 5 minutes, and the average of 2 measures was used for the analyses.	31-72	24-28	PMC3340926
cIMT	9	1,054-7,767	European descent	age, sex and other appropriate covariates (e.g. pc)	Summarized as the mean of the maximum of several measurements. For most studies, this was an average of multiple measurements from both the left and right arteries using high-resolution B-mode ultrasonography	43-76	25-29	PMC3257519
Carotid plaque	7	1,054-7,767	European descent	age, sex and other appropriate covariates (e.g. pc)	Either the presence of plaque or the proxy measure of stenosis >25% in carotid artery using high-resolution B-mode ultrasonography	43-76	25-29	PMC3257519

SUPPLEMENTARY DATA

Supplementary Table 4. Results of genotype risk score analysis.

Category	Trait	Unit	FI (18 variants)*		FI cluster 1		FI cluster 2		PPPIR3B		FTO		GCKR		BMI variants) (32)	
			beta	p	beta	p	beta	p	beta	p	beta	p	beta	P	beta	p
Non-disease metabolic traits of monogenic insulin resistance	SHBG (BMI adjusted)	natural log	-0.004	5x10⁻⁵	-0.010	9x10⁻¹³	0.003	0.2	-0.024	4x10⁻⁴	0.008	0.08	0.032	3x10⁻¹²	NA	NA
	HDL-C	SD	-0.015	3x10⁻³²	-0.020	7x10⁻³⁷	-0.003	0.2	-0.073	1x10⁻²²	-0.021	3x10⁻⁵	0.011	0.03	-0.010	4x10⁻²³
	Adiponectin (BMI adjusted)	log	-0.011	2x10⁻¹⁹	-0.015	2x10⁻²⁶	-0.005	0.03	-0.014	0.07	0.003	0.4	0.016	5x10⁻⁴	NA	NA
	BMI	SD	-0.002	0.1	-0.008	7x10⁻⁸	0.012	3x10⁻⁶	0.004	0.6	0.080	1x10⁻⁶²	0.008	0.09	0.036	7x10⁻²⁹⁹
	VATSAT ratio	z-score	0.010	9x10⁻⁶	0.015	6x10⁻⁷	0.006	0.2	0.010	0.3	-0.014	0.2	-0.016	0.1	-0.009	1x10⁻⁶
	CT measured hepatic steatosis	SD	0.000	0.9	0.021	3x10⁻⁴	-0.015	0.1	-0.251	6x10⁻¹⁶	0.026	0.1	-0.065	2x10⁻⁴	-0.007	0.04
	ALT	log10	0.002	3x10⁻⁶	0.002	3x10⁻⁵	0.001	0.2	0.008	0.006	0.002	0.3	0.001	0.7	0.002	2x10⁻⁶
Triglyceride	SD	0.004	3x10⁻⁴	0.018	4x10⁻²⁹	0.002	0.4	0.013	0.09	0.011	0.05	-0.112	7x10⁻¹²⁵	0.007	2x10⁻¹²	
Metabolic disease and disease related outcomes	Type 2 diabetes	OR	1.013	0.006	1.043	5x10⁻¹³	0.925	1x10⁻¹⁵	1.050	0.07	1.110	1x10⁻⁹	1.040	0.02	1.021	1x10⁻¹²
	Coronary artery disease	OR	1.014	7x10⁻⁹	1.013	1x10⁻⁵	1.016	4x10⁻⁴	1.005	0.6	1.014	0.1	1.017	0.09	1.010	1x10⁻⁷
	Systolic blood pressure (BMI adjusted)	mmHg	0.097	1x10⁻⁴	0.135	2x10⁻⁵	0.046	0.4	0.146	0.4	-0.120	0.2	-0.099	0.3	NA	NA
	Diastolic blood pressure (BMI adjusted)	mmHg	0.053	9x10⁻⁴	0.075	2x10⁻⁴	0.017	0.6	0.103	0.3	-0.142	0.02	-0.038	0.5	NA	NA
	cIMT	log	0.000	0.9	0.000	0.7	0.000	1	-0.001	0.6	0.002	0.1	0.001	0.3	0.001	0.06
Carotid plaques	OR	1.005	0.4	1.005	0.5	1.004	0.7	1.012	0.7	1.003	0.9	0.997	0.9	1.000	0.9	

Beta is the effect size per fasting insulin increasing allele on each trait.

Statistically significant P values (< 0.001) are shown in bold.

FI cluster 1 and 2 refer to the clusters of 11 and 5 fasting insulin variants respectively, from the hierarchical cluster analysis.

SD: Standard deviation; OR: odds ratio; VATSAT ratio: visceral-to-subcutaneous adipose tissue ratio.

NA in the table indicates that data uncorrected for BMI was not available.

* The genetic risk score excludes the genetic variant at *FTO* as it has a primary effect on BMI.

SUPPLEMENTARY DATA

Supplementary Table 5. Sensitivity analysis.

Trait	Unit	beta	p	W1-beta	W1-p	W2-beta	W2-p	W3-beta	W3-p
Non-disease metabolic traits of monogenic insulin resistance									
SHBG (BMI adjusted)	natural log	-0.010	9x10 ⁻¹³	-0.007	1x10 ⁻⁷	-0.007	1x10 ⁻¹⁴	-0.006	4x10 ⁻⁶
HDL-C	SD	-0.020	7x10 ⁻³⁷	-0.019	1x10 ⁻³⁶	-0.014	1x10 ⁻³⁷	-0.017	1 x10 ⁻³⁴
Adiponectin (BMI adjusted)	log	-0.015	2x10 ⁻²⁶	-0.011	3x10 ⁻¹⁶	-0.010	3x10 ⁻²⁶	-0.011	4 x10 ⁻¹⁷
BMI	SD	-0.008	7x10 ⁻⁸	-0.003	0.02	-0.006	4x10 ⁻⁰⁹	-0.004	0.005
VATSAT ratio	z-score	0.015	6x10 ⁻⁷	0.011	8x10 ⁻⁶	0.010	5x10 ⁻⁰⁷	0.011	2x10 ⁻⁵
CT measured hepatic steatosis	SD	0.021	3x10 ⁻⁴	0.017	0.002	0.014	3x10 ⁻⁴	0.011	0.03
ALT	log10	0.002	3x10 ⁻⁵	0.003	3x10 ⁻⁷	0.002	1x10 ⁻⁰⁵	0.002	8x10 ⁻⁷
Triglyceride	SD	0.018	4x10 ⁻²⁹	0.005	2x10 ⁻⁴	0.012	1x10 ⁻³⁰	0.002	0.1
Metabolic disease and disease related outcomes									
Type 2 diabetes	OR	1.043	5x10 ⁻¹³	1.027	1x10 ⁻⁶	1.031	1x10 ⁻¹⁵	1.032	5x10 ⁻⁹
Coronary artery disease	OR	1.013	1x10 ⁻⁵	1.013	2x10 ⁻⁷	1.008	3x10 ⁻⁰⁵	0.013	2x10 ⁻⁷
Systolic blood pressure (BMI adjusted)	mmHg	0.135	2x10 ⁻⁵	0.109	3x10 ⁻⁴	0.096	4x10 ⁻⁰⁶	0.108	3x10 ⁻⁴
Diastolic blood pressure (BMI adjusted)	mmHg	0.075	2x10 ⁻⁴	0.059	1x10 ⁻³	0.052	9x10 ⁻⁰⁵	0.060	9x10 ⁻⁴
cIMT	log	0.000	0.70	-0.000	0.7	0.000	0.7	-0.000	0.8
Carotid plaques	OR	1.005	0.50	1.006	0.3	1.004	0.4	1.007	0.3

SUPPLEMENTARY DATA

Supplementary Table 6. Results of genotype risk score analysis.

Category	Trait	Unit	FI cluster 1		FI cluster 1 excluding <i>IRS1</i>	
			beta	p	beta	p
Non-disease metabolic traits of monogenic insulin resistance	SHBG (BMI adjusted)	natural log	-0.010	9x10⁻¹³	-0.009	4x10⁻¹⁰
	HDL-C	SD	-0.020	7x10⁻³⁷	-0.019	5x10⁻³⁰
	Adiponectin (BMI adjusted)	log	-0.015	2x10⁻²⁶	-0.014	5x10⁻²²
	BMI	SD	-0.008	7x10⁻⁸	-0.008	2x10⁻⁶
	VATSAT ratio	z-score	0.015	6x10⁻⁷	0.013	3x10⁻⁵
	CT measured hepatic steatosis	SD	0.021	3x10⁻⁴	0.021	6x10⁻⁴
	ALT	log10	0.002	3x10⁻⁵	0.002	7x10⁻⁵
	Triglyceride	SD	0.018	4x10⁻²⁹	0.017	9x10⁻²⁴
Metabolic disease and disease related outcomes	Type 2 diabetes	OR	1.043	5x10⁻¹³	1.039	3x10⁻¹⁰
	Coronary artery disease	OR	1.013	1x10⁻⁵	1.013	4x10⁻⁵
	Systolic blood pressure (BMI adjusted)	mmHg	0.135	2x10⁻⁵	0.129	1x10⁻⁴
	Diastolic blood pressure (BMI adjusted)	mmHg	0.075	2x10⁻⁴	0.072	6x10⁻⁴
	cIMT	log	0.000	0.7	0.000	0.8
	Carotid plaques	OR	1.005	0.5	1.003	0.7

Beta is the effect size per fasting insulin increasing allele on each trait.


Statistically significant P values (< 0.001) are shown in bold.

FI cluster 1 refers to the clusters of 11 fasting insulin variants from the hierarchical cluster analysis.

SD: Standard deviation; OR: odds ratio; VATSAT ratio: visceral-to-subcutaneous adipose tissue ratio.

SUPPLEMENTARY DATA

Supplementary Figure 1. The estimated cumulative effect of the 11 “lipodystrophic insulin resistance” and 32 BMI variants on risk of type 2 diabetes and coronary artery disease. We used package “PredictABEL” in R (3) to simulate 2 separate genotype dataset for 50,000 individuals based on allele frequencies of 11 “lipodystrophic insulin resistance” and 32 BMI variants. We assumed (i) the genetic variants are independent (no linkage disequilibrium), (ii) there is no interaction between genetic variants, (iii) all genotypes are in Hardy-Weinberg equilibrium and (iv) the combined effect of genetic variants on disease risk follows “log additive” risk model. Individuals were grouped based on the number of “lipodystrophic insulin resistance” alleles (**a** and **c**) and BMI increasing alleles (**b** and **d**). The odds ratio of type 2 diabetes and coronary artery disease for each group is plotted (black circles). The superimposed histogram represents the proportion of samples with number of “lipodystrophic insulin resistance” or BMI increasing variants.



SUPPLEMENTARY DATA

References:

1. Scott RA, Lagou V, Welch RP, Wheeler E, Montasser ME, Luan J, Magi R, Strawbridge RJ, Rehnberg E, Gustafsson S, Kanoni S, Rasmussen-Torvik LJ, Yengo L, Lecoeur C, Shungin D, Sanna S, Sidore C, Johnson PC, Jukema JW, Johnson T, Mahajan A, Verweij N, Thorleifsson G, Hottenga JJ, Shah S, Smith AV, Sennblad B, Gieger C, Salo P, Perola M, Timpson NJ, Evans DM, Pourcain BS, Wu Y, Andrews JS, Hui J, Bielak LF, Zhao W, Horikoshi M, Navarro P, Isaacs A, O'Connell JR, Stirrups K, Vitart V, Hayward C, Esko T, Mihailov E, Fraser RM, Fall T, Voight BF, Raychaudhuri S, Chen H, Lindgren CM, Morris AP, Rayner NW, Robertson N, Rybin D, Liu CT, Beckmann JS, Willems SM, Chines PS, Jackson AU, Kang HM, Stringham HM, Song K, Tanaka T, Peden JF, Goel A, Hicks AA, An P, Muller-Nurasyid M, Franco-Cereceda A, Folkersen L, Marullo L, Jansen H, Oldehinkel AJ, Bruinenberg M, Pankow JS, North KE, Forouhi NG, Loos RJ, Edkins S, Varga TV, Hallmans G, Oksa H, Antonella M, Nagaraja R, Trompet S, Ford I, Bakker SJ, Kong A, Kumari M, Gigante B, Herder C, Munroe PB, Caulfield M, Antti J, Mangino M, Small K, Miljkovic I, Liu Y, Atalay M, Kiess W, James AL, Rivadeneira F, Uitterlinden AG, Palmer CN, Doney AS, Willemsen G, Smit JH, Campbell S, Polasek O, Bonnycastle LL, Hercberg S, Dimitriou M, Bolton JL, Fowkes GR, Kovacs P, Lindstrom J, Zemunik T, Bandinelli S, Wild SH, Basart HV, Rathmann W, Grallert H, Maerz W, Kleber ME, Boehm BO, Peters A, Pramstaller PP, Province MA, Borecki IB, Hastie ND, Rudan I, Campbell H, Watkins H, Farrall M, Stumvoll M, Ferrucci L, Waterworth DM, Bergman RN, Collins FS, Tuomilehto J, Watanabe RM, de Geus EJ, Penninx BW, Hofman A, Oostra BA, Psaty BM, Vollenweider P, Wilson JF, Wright AF, Hovingh GK, Metspalu A, Uusitupa M, Magnusson PK, Kyvik KO, Kaprio J, Price JF, Dedoussis GV, Deloukas P, Meneton P, Lind L, Boehnke M, Shuldiner AR, van Duijn CM, Morris AD, Toenjes A, Peyser PA, Beilby JP, Korner A, Kuusisto J, Laakso M, Bornstein SR, Schwarz PE, Lakka TA, Rauramaa R, Adair LS, Smith GD, Spector TD, Illig T, de Faire U, Hamsten A, Gudnason V, Kivimaki M, Hingorani A, Keinanen-Kiukaanniemi SM, Saaristo TE, Boomsma DI, Stefansson K, van der Harst P, Dupuis J, Pedersen NL, Sattar N, Harris TB, Cucca F, Ripatti S, Salomaa V, Mohlke KL, Balkau B, Froguel P, Pouta A, Jarvelin MR, Wareham NJ, Bouatia-Naji N, McCarthy MI, Franks PW, Meigs JB, Teslovich TM, Florez JC, Langenberg C, Ingelsson E, Prokopenko I, Barroso I: Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. *Nat Genet* 2012;44:991-1005
2. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, Lango Allen H, Lindgren CM, Luan J, Magi R, Randall JC, Vedantam S, Winkler TW, Qi L, Workalemahu T, Heid IM, Steinthorsdottir V, Stringham HM, Weedon MN, Wheeler E, Wood AR, Ferreira T, Weyant RJ, Segre AV, Estrada K, Liang L, Nemesh J, Park JH, Gustafsson S, Kilpelainen TO, Yang J, Bouatia-Naji N, Esko T, Feitosa MF, Kutalik Z, Mangino M, Raychaudhuri S, Scherag A, Smith AV, Welch R, Zhao JH, Aben KK, Absher DM, Amin N, Dixon AL, Fisher E, Glazer NL, Goddard ME, Heard-Costa NL, Hoesel V, Hottenga JJ, Johansson A, Johnson T, Ketkar S, Lamina C, Li S, Moffatt MF, Myers RH, Narisu N, Perry JR, Peters MJ, Preuss M, Ripatti S, Rivadeneira F, Sandholt C, Scott LJ, Timpson NJ, Tyrer JP, van Wingerden S, Watanabe RM, White CC, Wiklund F, Barlassina C, Chasman DI, Cooper MN, Jansson JO, Lawrence RW, Pellikka N, Prokopenko I, Shi J, Thiering E, Alavere H, Alibrandi MT, Almgren P, Arnold AM, Aspelund T, Atwood LD, Balkau B, Balmforth AJ, Bennett AJ, Ben-Shlomo Y, Bergman RN, Bergmann S, Biebermann H, Blakemore AI, Boes T, Bonnycastle LL, Bornstein SR, Brown MJ, Buchanan TA, Busonero F, Campbell H, Cappuccio FP, Cavalcanti-Proenca C, Chen YD, Chen CM, Chines PS, Clarke R, Coin L, Connell J, Day IN, den Heijer M, Duan J, Ebrahim S, Elliott P, Elosua R, Eiriksdottir G, Erdos MR, Eriksson JG, Facheris MF, Felix SB, Fischer-Posovszky P, Folsom AR, Friedrich N, Freimer NB, Fu M, Gaget S, Gejman PV, Geus EJ, Gieger C, Gjesing AP, Goel A, Goyette P, Grallert H, Grassler J, Greenawalt DM, Groves CJ, Gudnason V, Guiducci C, Hartikainen AL, Hassanali N, Hall AS, Havulinna AS, Hayward C, Heath AC, Hengstenberg C, Hicks AA, Hinney A, Hofman A, Homuth G, Hui J, Igl W, Iribarren C, Isomaa B, Jacobs KB, Jarick I, Jewell E, John U, Jorgensen T, Jousilahti P, Jula A, Kaakinen M, Kajantie E, Kaplan LM, Kathiresan S, Kettunen J, Kinnunen L, Knowles JW, Kolcic I, Konig IR, Koskinen S, Kovacs P, Kuusisto J, Kraft P, Kvaloy K, Laitinen J, Lantieri O, Lanzani C, Launer LJ, Lecoeur C, Lehtimaki T, Lettre G, Liu J, Lokki ML, Lorentzon M, Luben RN, Ludwig B, Manunta P, Marek D, Marre M, Martin NG, McArdle WL, McCarthy A, McKnight B, Meitinger T, Melander O, Meyre D, Midthjell K, Montgomery GW, Morken MA, Morris AP, Mulic R, Ngwa JS, Nelis M, Neville MJ, Nyholt DR, O'Donnell CJ, O'Rahilly S, Ong KK, Oostra B, Pare G, Parker AN, Perola M, Pichler I, Pietilainen KH, Platou CG, Polasek O, Pouta A, Rafelt S, Raitakari

SUPPLEMENTARY DATA

O, Rayner NW, Ridderstrale M, Rief W, Ruokonen A, Robertson NR, Rzehak P, Salomaa V, Sanders AR, Sandhu MS, Sanna S, Saramies J, Savolainen MJ, Scherag S, Schipf S, Schreiber S, Schunkert H, Silander K, Sinisalo J, Siscovick DS, Smit JH, Soranzo N, Sovio U, Stephens J, Surakka I, Swift AJ, Tammesoo ML, Tardif JC, Teder-Laving M, Teslovich TM, Thompson JR, Thomson B, Tonjes A, Tuomi T, van Meurs JB, van Ommen GJ, Vatin V, Viikari J, Visvikis-Siest S, Vitart V, Vogel CI, Voight BF, Waite LL, Wallaschofski H, Walters GB, Widen E, Wiegand S, Wild SH, Willemsen G, Witte DR, Witteman JC, Xu J, Zhang Q, Zgaga L, Ziegler A, Zitting P, Beilby JP, Farooqi IS, Hebebrand J, Huikuri HV, James AL, Kahonen M, Levinson DF, Macciardi F, Nieminen MS, Ohlsson C, Palmer LJ, Ridker PM, Stumvoll M, Beckmann JS, Boeing H, Boerwinkle E, Boomsma DI, Caulfield MJ, Chanock SJ, Collins FS, Cupples LA, Smith GD, Erdmann J, Froguel P, Gronberg H, Gyllensten U, Hall P, Hansen T, Harris TB, Hattersley AT, Hayes RB, Heinrich J, Hu FB, Hveem K, Illig T, Jarvelin MR, Kaprio J, Karpe F, Khaw KT, Kiemenev LA, Krude H, Laakso M, Lawlor DA, Metspalu A, Munroe PB, Ouwehand WH, Pedersen O, Penninx BW, Peters A, Pramstaller PP, Quertermous T, Reinehr T, Rissanen A, Rudan I, Samani NJ, Schwarz PE, Shuldiner AR, Spector TD, Tuomilehto J, Uda M, Uitterlinden A, Valle TT, Wabitsch M, Waeber G, Wareham NJ, Watkins H, Wilson JF, Wright AF, Zillikens MC, Chatterjee N, McCarroll SA, Purcell S, Schadt EE, Visscher PM, Assimes TL, Borecki IB, Deloukas P, Fox CS, Groop LC, Haritunians T, Hunter DJ, Kaplan RC, Mohlke KL, O'Connell JR, Peltonen L, Schlessinger D, Strachan DP, van Duijn CM, Wichmann HE, Frayling TM, Thorsteinsdottir U, Abecasis GR, Barroso I, Boehnke M, Stefansson K, North KE, McCarthy MI, Hirschhorn JN, Ingelsson E, Loos RJ: Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. *Nat Genet* 2010;42:937-948

3. Kundu S, Aulchenko YS, van Duijn CM, Janssens AC: PredictABEL: an R package for the assessment of risk prediction models. *European journal of epidemiology* 2011;26:261-264